Haemonetics PE ratio HAE

Share price divided by earnings per share over the last twelve months, since 2011.

Today, Oct 23, 2026: 58.1×
10-year median: 51.6×
Against its 10-year history: 60th; percentile: 0 is its lowest day, 100 its highest
10-year range: 14.7× to 279×
Peer median: 36.9×

Haemonetics' PE ratio is 58.1× as of Oct 23, 2026: a share price of $118.51 against $2.04 of earnings per share over the last twelve months.

That is above its ten-year median of 51.6×, close to the middle of its last ten years.

Over that time it ranged from 14.7× in Sep 2025 to 279× in Nov 2018.

The median for 10 medical instruments and supplies stocks of a similar size is 36.9×.

PE ratio over time

median 51.6×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	58.1×	14.9×	58.2×
2025	23.5×	14.7×	33.2×
2024	32.2×	29.4×	39.8×
2023	34.3×	31.9×	53.8×
2022	47.4×	47.2×	148×
2021	88.4×	26.5×	99.9×
2020	57.4×	43.1×	89.4×
2019	89.2×	89.2×	252×
2018	239×	104×	279×
2017	129×	121×	139×
2016	64.6×	61.2×	64.6×
2015	65.8×	63.5×	134×
2014	67.4×	43.3×	70.6×
2013	71.7×	40.8×	104×
2012	39.2×	22.4×	40.2×
2011	22.1×	18.8×	22.1×

Against its peers

Companies in Medical - Instruments & Supplies nearest Haemonetics' size, closest first, today.

Company	PE ratio
HAEHaemonetics	58.1×
MMSIMerit Medical Systems	38.6×
VNTVontier	14.3×
BMIBadger Meter	35.3×
ICUIICU Medical	141×
MSAMSA Safety	22.7×
NVSTEnvista	40.7×
WRBYWarby Parker	370×
ATRCAtriCure	281×
PODDInsulet	27.9×
GMEDGlobus Medical	20.8×
Peer median	36.9×

Where Haemonetics ranks

#30of 35Medical instruments and supplies stocks with the lowest PE ratio

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Haemonetics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.